Experimental acoustic characterization of an endoskeletal antibubble contrast agent: First results.

Saved in:

Bibliographic Details
Title:	Experimental acoustic characterization of an endoskeletal antibubble contrast agent: First results.
Authors:	Panfilova, Anastasiia¹ (AUTHOR) anastasiapanfilova09@gmail.com, Chen, Peiran¹ (AUTHOR), van Sloun, Ruud J.G.¹ (AUTHOR), Wijkstra, Hessel^1,2 (AUTHOR), Postema, Michiel^3,4 (AUTHOR), Poortinga, Albert T.⁵ (AUTHOR), Mischi, Massimo¹ (AUTHOR)
Source:	Medical Physics. Nov2021, Vol. 48 Issue 11, p6765-6780. 16p.
Subjects:	Contrast media, Ultrasound contrast media, Microbubbles, Contrast-enhanced ultrasound, Attenuation coefficients, Sound pressure
Abstract:	Purpose: An antibubble is an encapsulated gas bubble with an incompressible inclusion inside the gas phase. Current‐generation ultrasound contrast agents are bubble‐based: they contain encapsulated gas bubbles with no inclusions. The objective of this work is to determine the linear and nonlinear responses of an antibubble contrast agent in comparison to two bubble‐based ultrasound contrast agents, that is, reference bubbles and SonoVueTM. Methods: Side scatter and attenuation of the three contrast agents were measured, using single‐element ultrasound transducers, operating at 1.0, 2.25, and 3.5 MHz. The scatter measurements were performed at acoustic pressures of 200 and 300 kPa for 1.0 MHz, 300 kPa, and 450 kPa for 2.25 MHz, and 370 and 560 kPa for 3.5 MHz. Attenuation measurements were conducted at pressures of 13, 55, and 50 kPa for 1.0, 2.25, and 3.5 MHz, respectively. In addition, a dynamic contrast‐enhanced ultrasound measurement was performed, imaging the contrast agent flow through a vascular phantom with a commercial diagnostic linear array probe. Results: Antibubbles generated equivalent or stronger harmonic signal, compared to bubble‐based ultrasound contrast agents. The second harmonic side‐scatter amplitude of the antibubble agent was up to 3 dB greater than that of reference bubble agent and up to 4 dB greater than that of SonoVueTM at the estimated concentration of 8×104 bubbles/mL. For ultrasound with a center transmit frequency of 1.0 MHz, the attenuation coefficient of the antibubble agent was 8.7 dB/cm, whereas the attenuation coefficient of the reference agent was 7.7 and 0.3 dB/cm for SonoVueTM. At 2.25 MHz, the attenuation coefficients were 9.7, 3.0, and 0.6 dB/cm, respectively. For 3.5 MHz, they were 4.4, 1.8, and 1.0 dB/cm, respectively. A dynamic contrast‐enhanced ultrasound recording showed the nonlinear signal of the antibubble agent to be 31% greater than for reference bubbles and 23% lower than SonoVueTM at a high concentration of 2×106 bubbles/mL. Conclusion: Endoskeletal antibubbles generate comparable or greater higher harmonics than reference bubbles and SonoVueTM. As a result, antibubbles with liquid therapeutic agents inside the gas phase have high potential to become a traceable therapeutic agent. [ABSTRACT FROM AUTHOR]
	Copyright of Medical Physics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Engineering Source

Description
Abstract:	Purpose: An antibubble is an encapsulated gas bubble with an incompressible inclusion inside the gas phase. Current‐generation ultrasound contrast agents are bubble‐based: they contain encapsulated gas bubbles with no inclusions. The objective of this work is to determine the linear and nonlinear responses of an antibubble contrast agent in comparison to two bubble‐based ultrasound contrast agents, that is, reference bubbles and SonoVueTM. Methods: Side scatter and attenuation of the three contrast agents were measured, using single‐element ultrasound transducers, operating at 1.0, 2.25, and 3.5 MHz. The scatter measurements were performed at acoustic pressures of 200 and 300 kPa for 1.0 MHz, 300 kPa, and 450 kPa for 2.25 MHz, and 370 and 560 kPa for 3.5 MHz. Attenuation measurements were conducted at pressures of 13, 55, and 50 kPa for 1.0, 2.25, and 3.5 MHz, respectively. In addition, a dynamic contrast‐enhanced ultrasound measurement was performed, imaging the contrast agent flow through a vascular phantom with a commercial diagnostic linear array probe. Results: Antibubbles generated equivalent or stronger harmonic signal, compared to bubble‐based ultrasound contrast agents. The second harmonic side‐scatter amplitude of the antibubble agent was up to 3 dB greater than that of reference bubble agent and up to 4 dB greater than that of SonoVueTM at the estimated concentration of 8×104 bubbles/mL. For ultrasound with a center transmit frequency of 1.0 MHz, the attenuation coefficient of the antibubble agent was 8.7 dB/cm, whereas the attenuation coefficient of the reference agent was 7.7 and 0.3 dB/cm for SonoVueTM. At 2.25 MHz, the attenuation coefficients were 9.7, 3.0, and 0.6 dB/cm, respectively. For 3.5 MHz, they were 4.4, 1.8, and 1.0 dB/cm, respectively. A dynamic contrast‐enhanced ultrasound recording showed the nonlinear signal of the antibubble agent to be 31% greater than for reference bubbles and 23% lower than SonoVueTM at a high concentration of 2×106 bubbles/mL. Conclusion: Endoskeletal antibubbles generate comparable or greater higher harmonics than reference bubbles and SonoVueTM. As a result, antibubbles with liquid therapeutic agents inside the gas phase have high potential to become a traceable therapeutic agent. [ABSTRACT FROM AUTHOR]
ISSN:	00942405
DOI:	10.1002/mp.15242